Where we began
In early 2017 Dr. Neil Fleshner, a practicing urologist in Toronto, accompanied his first prostate cancer patient to Germany for an experimental new cancer treatment - radioligand therapy. The treatment was not available anywhere in North America – Dr. Fleshner and his patient had to travel to Germany, at significant expense, for it to be administered. Wanting to improve patient access to these advancements in cancer care, Dr. Fleshner began thinking about how a team could be assembled to build the infrastructure necessary to bring these innovative therapeutics to more people.
This seed of an idea resulted in the formation of POINT Biopharma.
POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. In addition to our exciting pipeline of radioligand molecules for a variety of cancers, we also operate our radiopharmaceutical production facility in Indianapolis, Indiana which is capable of servicing all of North America as well as many global locations.
Our leadership team
We are a diverse group with a shared goal: to transform lives touched by cancer. With collaboration and innovation, we will change health care, for good.